The purpose of this project is to determine which mechanisms are the effective components of the CD8 T cell role in tumor rejection in vivo and determine how they act. The investigator will generate in vitro CTL responses to the tumor antigens of P815 using CD8 T cells from DBA/2 mice under conditions leading to T1 or T2 populations of effector T cells. He will measure the cytokine secretion, CTL activity and surface phenotype of the effector populations. In parallel cultures, he will use CD8 T cells from C57BL/6 mice to generate in vitro responses to the tumor antigens of EL-4. The effector populations will be adoptively transferred to syngeneic recipients. The effectiveness of the T1 and T2 populations will be assessed in their ability to reject already established tumors. The cell types involved in tumor rejection will be characterized. It is a central hypothesis of this study, that the cytokines liberated by the T1 and T2 populations when they encounter the tumor antigen in the host will exert a crucial influence on the nature of the host response and the likelihood of tumor rejection. The investigator will further analyze the cellular and molecular mechanisms involved in tumor rejection by generating CD8 effectors in cytokine knock out mice and by using various immunodeficient and cytokine knockout mice as recipients.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA071833-03
Application #
2895652
Study Section
Experimental Immunology Study Section (EI)
Program Officer
Hecht, Toby T
Project Start
1997-05-15
Project End
2000-04-30
Budget Start
1999-05-01
Budget End
2000-04-30
Support Year
3
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Trudeau Institute, Inc.
Department
Type
DUNS #
City
Saranac Lake
State
NY
Country
United States
Zip Code
12983
Garcia-Hernandez, Maria de la Luz; Hamada, Hiromasa; Reome, Joyce B et al. (2010) Adoptive transfer of tumor-specific Tc17 effector T cells controls the growth of B16 melanoma in mice. J Immunol 184:4215-27
Hollenbaugh, Joseph A; Dutton, Richard W (2006) IFN-gamma regulates donor CD8 T cell expansion, migration, and leads to apoptosis of cells of a solid tumor. J Immunol 177:3004-11
Dobrzanski, Mark J; Reome, Joyce B; Hollenbaugh, Joseph A et al. (2004) Effector cell-derived lymphotoxin alpha and Fas ligand, but not perforin, promote Tc1 and Tc2 effector cell-mediated tumor therapy in established pulmonary metastases. Cancer Res 64:406-14
Dobrzanski, Mark J; Reome, Joyce B; Hollenbaugh, Joseph A et al. (2004) Tc1 and Tc2 effector cell therapy elicit long-term tumor immunity by contrasting mechanisms that result in complementary endogenous type 1 antitumor responses. J Immunol 172:1380-90
Woodland, David L; Dutton, Richard W (2003) Heterogeneity of CD4(+) and CD8(+) T cells. Curr Opin Immunol 15:336-42
Dobrzanski, M J; Reome, J B; Dutton, R W (2001) Immunopotentiating role of IFN-gamma in early and late stages of type 1 CD8 effector cell-mediated tumor rejection. Clin Immunol 98:70-84
Helmich, B K; Dutton, R W (2001) The role of adoptively transferred CD8 T cells and host cells in the control of the growth of the EG7 thymoma: factors that determine the relative effectiveness and homing properties of Tc1 and Tc2 effectors. J Immunol 166:6500-8
Dobrzanski, M J; Reome, J B; Dutton, R W (2001) Role of effector cell-derived IL-4, IL-5, and perforin in early and late stages of type 2 CD8 effector cell-mediated tumor rejection. J Immunol 167:424-34
Dobrzanski, M J; Reome, J B; Dutton, R W (2000) Type 1 and type 2 CD8+ effector T cell subpopulations promote long-term tumor immunity and protection to progressively growing tumor. J Immunol 164:916-25
Dobrzanski, M J; Reome, J B; Dutton, R W (1999) Therapeutic effects of tumor-reactive type 1 and type 2 CD8+ T cell subpopulations in established pulmonary metastases. J Immunol 162:6671-80